After the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...

Wockhardt Ltd has secured approval from the CDSCO for its new antibiotic, Zaynich. This drug is developed in India and will be used to trea...

Tata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...

Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...

Iran faces severe economic hardship due to war and US sanctions. Prices for essentials like food and medicine have surged. Job losses and b...

Indian developers are showcasing innovative apps for the Apple ecosystem. These apps focus on personal experiences, design, and AI. Develop...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

In the April 2022-September 2024 bull market, every management appeared capable. Margins expanded, working capital looked manageable, capit...

India is taking a groundbreaking step forward in the realm of rare disease care with a distinctive approach that champions local ingenuity ...

Over the next few sessions, as the uncertainty caused by the Gulf war intensifies and makes you anxious, remember this: It is not the first...

In situations of financial distress, parents may themselves need help and support. Many of us that live the good life can look out to help ...

Gilead will pay $115 per share in cash at the deal's closing, which is at a premium of 79% to the stock's last close. Kite Pharma, a unit ?...

A homegrown CAR T therapy developed at Israel’s Rabin Medical Centre is giving new hope to Multiple Myeloma patients who have run out of tr...

India has reached a milestone in cancer treatment with the first successful allogeneic CAR-T therapy at P. D. Hinduja Hospital, led by Dr. ...

Aurigene Oncology has announced promising phase-1 results for its novel CAR-T cell therapy, Ribrecabtagene autoleucel, in patients with mul...

CAR-T therapies, previously not available in India, have shown promising results for patients who have exhausted all other means of treatme...

As per the agreement, Laurus will acquire 26.62% stake (fully diluted basis) for a cash consideration of approximately Rs 46 crores, subjec...